Evaluation of cisplatin combined with piroxicam for the treatment of oral malignant melanoma and oral squamous cell carcinoma in dogs

Pedro A. Boria, Daryl J. Murry, Peter F. Bennett, Nita W. Glickman, Paul W. Snyder, Brenna L. Merkel, Deborah L. Schlittler, Anthony J. Mutsaers, Rose M. Thomas, Deborah W. Knapp

Research output: Contribution to journalArticle

80 Citations (Scopus)

Abstract

Objective-To determine the maximum tolerated dose (MTD) of cisplatin administered with piroxicam, the antitumor activity and toxicity of cisplatin combined with piroxicam in dogs with oral malignant melanoma (OMM) and oral squamous cell carcinoma (SCC), and the effects of piroxicam on the pharmacokinetics of cisplatin in dogs with tumors. Design-Prospective nonrandomized clinical trial. Animals-25 dogs. Procedure-Dogs were treated with a combination of cisplatin (escalating dose with 6 hours of diuresis with saline [0.9% NaCl] solution) and piroxicam (0.3 mg/kg [0.14 mg/lb], PO, q 24 h). The initial cisplatin dose (50 mg/m2) was increased by 5 mg/m 2 until the MTD was reached. Tumor stage and size were determined at 6-week intervals during treatment. The pharmacokinetics of cisplatin were determined in dogs receiving a combination of cisplatin and piroxicam during the clinical trial and dogs that were treated with cisplatin alone. Results-11 dogs with OMM and 9 dogs with SCC were included in the clinical trial. The MTD of cisplatin when administered in combination with piroxicam was 50 mg/m 2. Tumor remission occurred in 5 of 9 dogs with SCC and 2 of 11 dogs with OMM. The most common abnormality observed was renal toxicosis. Clearance of cisplatin in dogs that were treated with cisplatin alone was not significantly different from that in dogs treated with a combination of cisplatin and piroxicam. Conclusions and Clinical Relevance-Cisplatin administered in combination with piroxicam had antitumor activity against OMM and SCC. The level of toxicity was acceptable, although renal function must be monitored carefully.

Original languageEnglish (US)
Pages (from-to)388-394
Number of pages7
JournalJournal of the American Veterinary Medical Association
Volume224
Issue number3
DOIs
StatePublished - Feb 1 2004

Fingerprint

Piroxicam
cisplatin
squamous cell carcinoma
melanoma
Cisplatin
Squamous Cell Carcinoma
Melanoma
mouth
Dogs
dogs
Maximum Tolerated Dose
dosage
pharmacokinetics
neoplasms
clinical trials
Pharmacokinetics
Clinical Trials
toxicity
Kidney
diuresis

ASJC Scopus subject areas

  • veterinary(all)

Cite this

Evaluation of cisplatin combined with piroxicam for the treatment of oral malignant melanoma and oral squamous cell carcinoma in dogs. / Boria, Pedro A.; Murry, Daryl J.; Bennett, Peter F.; Glickman, Nita W.; Snyder, Paul W.; Merkel, Brenna L.; Schlittler, Deborah L.; Mutsaers, Anthony J.; Thomas, Rose M.; Knapp, Deborah W.

In: Journal of the American Veterinary Medical Association, Vol. 224, No. 3, 01.02.2004, p. 388-394.

Research output: Contribution to journalArticle

Boria, Pedro A. ; Murry, Daryl J. ; Bennett, Peter F. ; Glickman, Nita W. ; Snyder, Paul W. ; Merkel, Brenna L. ; Schlittler, Deborah L. ; Mutsaers, Anthony J. ; Thomas, Rose M. ; Knapp, Deborah W. / Evaluation of cisplatin combined with piroxicam for the treatment of oral malignant melanoma and oral squamous cell carcinoma in dogs. In: Journal of the American Veterinary Medical Association. 2004 ; Vol. 224, No. 3. pp. 388-394.
@article{ed6c9b1d652d4de69bbb43e516a23dad,
title = "Evaluation of cisplatin combined with piroxicam for the treatment of oral malignant melanoma and oral squamous cell carcinoma in dogs",
abstract = "Objective-To determine the maximum tolerated dose (MTD) of cisplatin administered with piroxicam, the antitumor activity and toxicity of cisplatin combined with piroxicam in dogs with oral malignant melanoma (OMM) and oral squamous cell carcinoma (SCC), and the effects of piroxicam on the pharmacokinetics of cisplatin in dogs with tumors. Design-Prospective nonrandomized clinical trial. Animals-25 dogs. Procedure-Dogs were treated with a combination of cisplatin (escalating dose with 6 hours of diuresis with saline [0.9{\%} NaCl] solution) and piroxicam (0.3 mg/kg [0.14 mg/lb], PO, q 24 h). The initial cisplatin dose (50 mg/m2) was increased by 5 mg/m 2 until the MTD was reached. Tumor stage and size were determined at 6-week intervals during treatment. The pharmacokinetics of cisplatin were determined in dogs receiving a combination of cisplatin and piroxicam during the clinical trial and dogs that were treated with cisplatin alone. Results-11 dogs with OMM and 9 dogs with SCC were included in the clinical trial. The MTD of cisplatin when administered in combination with piroxicam was 50 mg/m 2. Tumor remission occurred in 5 of 9 dogs with SCC and 2 of 11 dogs with OMM. The most common abnormality observed was renal toxicosis. Clearance of cisplatin in dogs that were treated with cisplatin alone was not significantly different from that in dogs treated with a combination of cisplatin and piroxicam. Conclusions and Clinical Relevance-Cisplatin administered in combination with piroxicam had antitumor activity against OMM and SCC. The level of toxicity was acceptable, although renal function must be monitored carefully.",
author = "Boria, {Pedro A.} and Murry, {Daryl J.} and Bennett, {Peter F.} and Glickman, {Nita W.} and Snyder, {Paul W.} and Merkel, {Brenna L.} and Schlittler, {Deborah L.} and Mutsaers, {Anthony J.} and Thomas, {Rose M.} and Knapp, {Deborah W.}",
year = "2004",
month = "2",
day = "1",
doi = "10.2460/javma.2004.224.388",
language = "English (US)",
volume = "224",
pages = "388--394",
journal = "Journal of the American Veterinary Medical Association",
issn = "0003-1488",
publisher = "American Veterinary Medical Association",
number = "3",

}

TY - JOUR

T1 - Evaluation of cisplatin combined with piroxicam for the treatment of oral malignant melanoma and oral squamous cell carcinoma in dogs

AU - Boria, Pedro A.

AU - Murry, Daryl J.

AU - Bennett, Peter F.

AU - Glickman, Nita W.

AU - Snyder, Paul W.

AU - Merkel, Brenna L.

AU - Schlittler, Deborah L.

AU - Mutsaers, Anthony J.

AU - Thomas, Rose M.

AU - Knapp, Deborah W.

PY - 2004/2/1

Y1 - 2004/2/1

N2 - Objective-To determine the maximum tolerated dose (MTD) of cisplatin administered with piroxicam, the antitumor activity and toxicity of cisplatin combined with piroxicam in dogs with oral malignant melanoma (OMM) and oral squamous cell carcinoma (SCC), and the effects of piroxicam on the pharmacokinetics of cisplatin in dogs with tumors. Design-Prospective nonrandomized clinical trial. Animals-25 dogs. Procedure-Dogs were treated with a combination of cisplatin (escalating dose with 6 hours of diuresis with saline [0.9% NaCl] solution) and piroxicam (0.3 mg/kg [0.14 mg/lb], PO, q 24 h). The initial cisplatin dose (50 mg/m2) was increased by 5 mg/m 2 until the MTD was reached. Tumor stage and size were determined at 6-week intervals during treatment. The pharmacokinetics of cisplatin were determined in dogs receiving a combination of cisplatin and piroxicam during the clinical trial and dogs that were treated with cisplatin alone. Results-11 dogs with OMM and 9 dogs with SCC were included in the clinical trial. The MTD of cisplatin when administered in combination with piroxicam was 50 mg/m 2. Tumor remission occurred in 5 of 9 dogs with SCC and 2 of 11 dogs with OMM. The most common abnormality observed was renal toxicosis. Clearance of cisplatin in dogs that were treated with cisplatin alone was not significantly different from that in dogs treated with a combination of cisplatin and piroxicam. Conclusions and Clinical Relevance-Cisplatin administered in combination with piroxicam had antitumor activity against OMM and SCC. The level of toxicity was acceptable, although renal function must be monitored carefully.

AB - Objective-To determine the maximum tolerated dose (MTD) of cisplatin administered with piroxicam, the antitumor activity and toxicity of cisplatin combined with piroxicam in dogs with oral malignant melanoma (OMM) and oral squamous cell carcinoma (SCC), and the effects of piroxicam on the pharmacokinetics of cisplatin in dogs with tumors. Design-Prospective nonrandomized clinical trial. Animals-25 dogs. Procedure-Dogs were treated with a combination of cisplatin (escalating dose with 6 hours of diuresis with saline [0.9% NaCl] solution) and piroxicam (0.3 mg/kg [0.14 mg/lb], PO, q 24 h). The initial cisplatin dose (50 mg/m2) was increased by 5 mg/m 2 until the MTD was reached. Tumor stage and size were determined at 6-week intervals during treatment. The pharmacokinetics of cisplatin were determined in dogs receiving a combination of cisplatin and piroxicam during the clinical trial and dogs that were treated with cisplatin alone. Results-11 dogs with OMM and 9 dogs with SCC were included in the clinical trial. The MTD of cisplatin when administered in combination with piroxicam was 50 mg/m 2. Tumor remission occurred in 5 of 9 dogs with SCC and 2 of 11 dogs with OMM. The most common abnormality observed was renal toxicosis. Clearance of cisplatin in dogs that were treated with cisplatin alone was not significantly different from that in dogs treated with a combination of cisplatin and piroxicam. Conclusions and Clinical Relevance-Cisplatin administered in combination with piroxicam had antitumor activity against OMM and SCC. The level of toxicity was acceptable, although renal function must be monitored carefully.

UR - http://www.scopus.com/inward/record.url?scp=9144244174&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9144244174&partnerID=8YFLogxK

U2 - 10.2460/javma.2004.224.388

DO - 10.2460/javma.2004.224.388

M3 - Article

C2 - 14765798

AN - SCOPUS:9144244174

VL - 224

SP - 388

EP - 394

JO - Journal of the American Veterinary Medical Association

JF - Journal of the American Veterinary Medical Association

SN - 0003-1488

IS - 3

ER -